HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer

Alexia L. Weeks1,2, Scott G. Wilson1,2,3, Lynley Ward1, Jack Goldblatt4,5, Jennie Hui6,7 and John P. Walsh1,2*

Abstract

Background: The genetic basis of nonsyndromic familial nonmedullary thyroid cancer (FNMTC) is poorly understood. A recent study identified HABP2 as a tumor suppressor gene and identified a germline variant (G534E) in an extended FNMTC kindred. The relevance of this to other FNMTC kindreds is uncertain.

Methods: Sanger sequencing was performed on peripheral blood DNA from probands from 37 Australian FNMTC kindreds to detect the G534E variant. Whole exome data from 59 participants from 20 kindreds were examined for mutations in HABP2 and the thyroid cancer susceptibility genes SRGAP1, NKX2-1, SRRM2 and FOXE1. The population prevalence of the G534E variant in HABP2 was examined in two independent cohorts.

Results: Heterozygosity for the G534E variant in HABP2 was found in 1 of 37 probands (2.7 %), but did not cosegregate with disease in this kindred, being absent in the proband’s affected sister. From whole exome data, pathogenic mutations were not identified in HABP2, SRGAP1, NKX2-1, SRRM2 or FOXE1. Heterozygosity for the G534E variant in HABP2 was present in 7.6 % of Busselton Health Study participants (N = 4634, unknown disease status) and 9.3 % of TwinsUK participants (N = 1195, no history of thyroid cancer).

Conclusions: The G534E variant in HABP2 does not account for the familial nature of NMTC in Australian kindreds, and is common in the general population. Further research is required to elucidate the genetic basis of nonsyndromic FNMTC.

Keywords: Papillary thyroid cancer, Thyroid carcinoma, Oncogenes, HABP2

Background

Thyroid cancer is one of the most common endocrine malignancies, accounting for 95 % of malignancies in endocrine organs [1]. The incidence of thyroid cancer is increasing worldwide, and in the US alone has almost tripled in the last 30 years [1, 2]. Nonmedullary thyroid cancers (NMTC) account for over 95 % of thyroid cancers [3]. These cancers are of follicular origin and are comprised of papillary (PTC) (accounting for 85 % of NMTC), follicular (11 %), Hürthle cell (3 %) and anaplastic histotypes (1 %). The remaining 5 % of thyroid cancers, medullary thyroid cancer (MTC), arise from the parafollicular C cells [4]. NMTC shows significant heritability, with an 8 to 10-fold increased risk in first-degree relatives of affected individuals [5]. Nonsyndromic familial nonmedullary thyroid cancer (FNMTC) is thought to account for approximately 3.5–10 % of all NMTC [6]. It is defined by the presence of thyroid cancer of follicular cell origin in 2 or more first-degree relatives, in the absence of a recognized familial cancer syndrome (such as Cowden syndrome or familial adenomatous polyposis) [7]. Both familial and sporadic NMTC are more common in women than men [8].

Whilst it seems clear that there is a hereditary basis to nonsyndromic FNMTC, until recently no specific genetic mutation has been discovered with a confirmed role in etiology [9]. Studies investigating the basis of FNMTC have identified 4 susceptibility genes, SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), FOXE1 (Forkhead Box E1), SRRM2 (Serine/Arginine Repetitive Matrix 2) and NKX2.1 (NK2 Homeobox 1) [10–12]. A number of
susceptibility candidate chromosomal loci were also identified, at 1q21, 6q22, 8p23.1-p22 and 8q24 [13]. It has been suggested that FNMT is an autosomal dominant condition with incomplete penetrance and variable expressivity, but the exact mode of inheritance remains unknown [14]. Alternatively, FNMT may be a polygenic disease caused by a low-to-moderate number of low-penetrant alleles [5].

In a recent study, Gara et al. identified $HABP2$ (Hyaluronan Binding Protein 2) as a novel causative gene in FNMT. A single $G \rightarrow A$ substitution (G534E) in exon 13 was associated with FNMT in a kindred with 7 affected individuals [15]. Using expression studies and cell transformation assays, the study provided evidence that $HABP2$ is a tumor-suppressor gene. The G534E variant was also found in 19 of 423 (4.7 %) multi-ethnic patients with PTC from the Cancer Genome Atlas (TCGA), as compared with 0.7 % of individuals with unknown disease status.

In subsequent editorial correspondence, however, it was reported that the G534E variant in $HABP2$ was not detected in 12 FNMT kindreds or 217 sporadic PTC cases from China [16], and it was suggested that in some populations, the prevalence of the G543E variant was much higher than 0.7 %, and as high as 3–5.7 % [17–19].

Several additional studies have now been published. Tomas et al. identified the G534E variant in 61.6 % of familial cases, 8.0 % of sporadic cases and 8.7 % of controls, and found that the variant did not cosegregate with NMTC in several kindreds [20]. In a study of 2105 NMTC cases from the British Isles, the frequency of the variant was 4.2 % in cases and 4.6 % in controls [21]. In a study from Saudi Arabia, Alzahrani et al. found no association between the variant and familial or sporadic NMTC compared with controls [22]. These studies, therefore, do not support an association between the variant and NMTC. In contrast, in a study from China, Zhang et al. identified the variant in 6 affected subjects from 4 kindreds, consistent with $HABP2$ being a FNMT susceptibility gene [23].

The association between this variant and NMTC is therefore somewhat controversial. To address this, we investigated a collection of 37 FNMT kindreds for the presence of this variant using Sanger sequencing. We examined whole exome data from a subset of kindreds for other pathogenic missense variants in $HABP2$ and for mutations in $SRGAP1$, $NKK2-1$, $SRRM2$ and $FOXE1$. We also determined the population prevalence of the G543E variant in $HABP2$ in two independent cohorts.

**Methods**

Starting in November 2009, we recruited affected and unaffected members of kindreds to a study of the genetic basis of nonsyndromic FNMT, initially using a candidate gene approach and subsequently using whole exome sequencing. The setting of the study was a tertiary referral center in Western Australia. Probands and kindreds were referred by clinicians (endocrinologists, surgeons and nuclear medicine physicians) and also identified from the Familial Cancer Registry of Genetic Services of Western Australia. DNA was extracted from peripheral whole blood using QIAGEN QIAamp DNA Blood mini or midi kits (QIAGEN Pty, Chadstone, Victoria, Australia) according to manufacturer’s instructions. Quantification was performed using the NanoDrop2000. Sanger sequencing of exon 13 of $HABP2$ (including the G534E variant) was performed on DNA from probands from each kindred using primers as described by Gara et al. [15] Sanger sequencing was performed by the Australian Genome Research Facility (AGRF;www.agrf.org.au) and data analyzed using Geneious (Biomatters Ltd., Auckland, New Zealand). Whole exome capture and sequencing was performed by AGRF and by Lotterywest State Biomedical Facility Genomics (Perth, Western Australia) using Illumina HiSeq2000 and Applied Biosystems 5500 SOLID systems. Exome capture was performed using SureSelect Human All Exon V5 + UTRs, TargetSeq Exome Enrichment System and TruSeq Exome Enrichment kit. We captured and sequenced coding regions to a mean depth of 68.7× which was sufficient to call variants at ~98 % of each targeted exome. An average of 87,245,482 reads were generated per affected individual as paired end, 100 bp reads. The exome data were annotated using ANNOVAR [24] and examined for pathogenic missense, splice-site, nonsense and start-gained variants in the $HABP2$ gene, as well as novel and previously identified variants in the $SRGAP1$, $NKK2-1$, $SRRM2$ and $FOXE1$ genes, using Varsifter software [25]. The predictive tools Polyphen-2, SIFT and MutationTaster were used to determine pathogenicity of detected variants and Minor allele frequency data from the 1000 Genomes Project was used to determine population frequency.

The population frequency of the G534E variant was estimated using deeply imputed genome wide association (GWA) data from 4634 participants in the 1994-5 Busselton Health Study (www.bpmri.org.au) a community-based, mainly White cohort from Western Australia. Genotyping was performed using the Illumina 610Q and 660W arrays, with results imputed to the 1000 Genomes (Build 37) reference panel, as previously described [26]. The frequency of the variant by direct genotyping was as determined from next-generation sequence data from 1195 participants in the TwinsUK cohort (www.twinsuk.ac.uk). These participants were euthyroid, with no history of thyroid surgery or thyroxine treatment. Next-generation sequencing was performed using the Illumina HiSeq platform and aligned to GRCh37 human reference sequence as previously described [26].
The study was approved by the Sir Charles Gairdner Group Human Research Ethics Committee (trial no. 2009-128). Written informed consent was provided by all participants.

**Results**

We recruited 109 participants from 37 kindreds with nonsyndromic FNMTC to the study. The number of individuals with thyroid cancer ranged from 2 to 6 per kindred; in 28 kindreds there were 2 affected individuals, in 9 kindreds there were 3 or more affected individuals. The ethnicity was Caucasian for 33 kindreds and Asian for 4 kindreds (Table 1).

Sanger sequencing was performed on peripheral blood DNA from probands from each kindred in order to detect the G534E variant in *HABP2*. Heterozygosity for the G534E variant was detected in a proband from a single kindred (Fig. 1a). The pedigree is illustrated in Fig. 1b. The proband was a white female who underwent facial irradiation for acne at age 16, and presented in 1993 at age 46 with bilateral thyroid nodules. Fine needle aspiration biopsy from the right lobe of thyroid was consistent with Hürthle cell neoplasm, and from the left lobe was consistent with hemorrhage into a thyroid nodule. Total thyroidectomy was performed. Histopathology of the right lobe showed a 30 mm follicular variant of PTC, a 20 mm hemorrhagic Hürthle cell adenoma and two further small foci of PTC. In the left lobe, there were multiple Hürthle cell adenomas up to 25 mm in diameter and a further small focus of PTC. One of 2 excised lymph nodes contained metastatic PTC. Radioactive iodine (3000 MBq) was administered, with no evidence of distant metastases on the post-therapy scan (stage T2N1MO). There has been no evidence of recurrence during follow-up. The proband’s son also has the G534E variant. He has no significant medical history, but has not yet been assessed clinically or sonographically for thyroid neoplasia.

The proband’s affected sister underwent a right hemithyroidectomy in 1985 at age 36 for a thyroid nodule. Histopathology was of follicular adenoma, with an incidental finding of a single focus of papillary microcancer. At age 55 she developed a left sided thyroid nodule and underwent completion thyroidectomy. Histopathology revealed a 13 mm predominantly cystic PTC with an additional 3mm focus of follicular variant of PTC (stage T1NXMX). She did not receive radioiodine treatment and there has been no evidence of recurrence during follow-up. Sanger sequencing on this individual revealed wild type results, without the G534E variant in *HABP2*.

The G534E variant in *HABP2* was not found in probands from the remaining 36 kindreds by Sanger sequencing. Whole exome sequencing data were available from 59 individuals (50 affected, 9 unaffected) from 20 FNMTC kindreds, of which 7 kindreds had 2 affected individuals and 13 kindreds had 3 or more affected individuals, and were examined for the G534E variant and other pathogenic missense variants in *HABP2*; none were identified. The whole exome data were also examined for variants previously reported as associated with NMTC in *SRGAP1* (Q149H, R617C), *FOXE1* (A248G), *SRRM2* (S346F) and *NKX2.1* (A339V) and for novel pathogenic mutations in these genes; none were identified in the kindreds.

The population frequency of the G534E variant was determined from two independent cohorts. Of 4634 participants in the 1994-5 Busselton Health Study (with unknown thyroid cancer status), 351 (7.6 %) were heterozygous for the variant (from imputed genotypes), whereas 4 were homozygous, giving a minor allele frequency of 3.9 %. From directly genotyped next-generation sequence data from 1195 participants in the TwinsUK study who had no history of thyroid cancer or other thyroid diseases, 111 (9.3 %) were heterozygous for the variant and 1 individual was homozygous, giving a minor allele frequency of 4.7 %.

| Table 1 Characteristics of 37 FPTC probands |
|---------------------------------------------|
| **Characteristic**                        | **Patients (N = 37)** |
| Age at diagnosis (SD)                      | 46.7 (15.9) |
| Female N (%)                              | 27 (73.0 %) |
| Ethnicity                                 |              |
| Caucasian                                 | 33 (89.2 %) |
| Asian                                     | 4 (10.8 %) |
| Histological subtype                      |              |
| Papillary                                 | 30 (81.1 %) |
| Papillary (follicular variant)             | 6 (16.2 %) |
| Papillary (tall cell variant)              | 1 (2.7 %) |
| Multifocal                                | 25 (67.6 %) |
| TNM staging                               |              |
| T1 N0 M0                                  | 10           |
| T2 N0 M0                                  | 5            |
| T3 N0 M0                                  | 1            |
| T4 N0 M0                                  |              |
| T1 N1 M0                                  | 5            |
| T2 N1 M0                                  | 7            |
| T3 N1 M0                                  | 5            |
| T4 N1 M0                                  | 3            |
| Staging                                   |              |
| I                                         | 23 (63.9 %)  |
| II                                        | 3 (8.3 %)    |
| III                                       | 6 (16.7 %)   |
| IV                                        | 4 (11.1 %)   |

*Available for 36 probands. Detailed histopathology not available for one proband who underwent surgery in 1983.
Discussion
This study examined the frequency of the recently identified G534E variant in HABP2 in a sample of FNMTC kindreds. We identified the variant in only 1 of 37 kindreds (2.7%). The proband in this kindred had unusual thyroid histopathology, with multiple Hürthle cell adenomas as well as multifocal PTC. She had previously undergone head and neck irradiation for acne, a well-recognized risk factor for thyroid cancer, which occurs in up to 31% of individuals receiving this treatment [27]. Her histopathology presumably reflects the extensive mutagenic effects of ionizing radiation combined with genetic predisposition to thyroid neoplasia. In this kindred, the variant did not cosegregate with the disease, being absent in her sibling, who had multifocal PTC. There are two possible explanations for this. The sister may represent a phenocopy, as thyroid cancer can affect two members of the same family by chance or because of shared environmental rather than genetic factors [28]. Alternatively, it may be that these two siblings share pathogenic mutations in as yet unidentified susceptibility genes.

The frequency of the G534E variant carriers in two independent cohorts was 7.6 and 9.3%, indicating that this is in fact a common polymorphism, rather than a rare variant. The frequency in the 37 probands was somewhat lower (2.7%), showing that this variant does not explain the familial aggregation of NMTC in the kindreds studied. Gara et al. reported the G534E mutation in 4.7% of a sample of patients with PTC from TCGA [15], and our results are broadly consistent with that. Gara et al. also provided evidence from functional studies that HABP2 is a tumor suppressor gene, and that the G534E variant results in loss of function. It remains possible that the G534E variant in HABP2 is a susceptibility locus for cancer, but further studies are required to determine that. Other associations have been reported for the G534E variant of HABP2 including thrombophilia,
carotid stenosis and venous thromboembolism [29, 30], but neither the proband nor her son (who also carries this variant) have hematological or vascular disorders.

We also examined whole exome data for other missense mutations in HABP2 and for variants which are thought to play a role in FNMTC in the known susceptibility genes, SRGAP1, SRRM2, FOXE1 and NKK2.1. However, none of those genes had pathogenic variants identified in our study. Thus, the genetic basis of FNMTC in these kindreds remains to be determined.

Strengths of our study include the number of FNMTC kindreds recruited, and the use of both whole exome and Sanger sequencing to identify pathogenic mutations. A limitation is that not all members of all kindreds have undergone exome sequencing to date. Many of the kindreds studied had only two affected members which, as noted above, could occur by chance.

Conclusions
In conclusion, we report that the G534E variant in HABP2 is uncommon in FNMTC kindreds. Its frequency in general population indicates that it is a common polymorphism, and its role (if any) in the pathogenesis of thyroid cancer remains to be determined. Therefore the clinical yield of sequencing this variant in affected kindreds is likely to be small. The genetic basis of nonsyndromic FNMTC remains largely unknown, and more research is urgently required to elucidate this. In the meantime, the management of nonsyndromic FNMTC kindreds remains primarily clinical, as genetic testing has a minimal contribution to offer.

Abbreviations
FNMTC, familial nonmedullary thyroid cancer; FOXE1, Forkhead Box E1; GWA, Genome Wide Association; HABP2, hyaluronan binding protein 2; MBq, megabequerels; MTC, medullary thyroid cancer; NKX2-1, NK2 Homeobox 1; NMTC, nonmedullary thyroid cancer; PTC, papillary thyroid cancer; SRGAP1, SLIT-ROBO Rho GTPase Activating Protein 1; SRRM2, Serine/Arginine Repetitive Matrix 2; TCGA, The Cancer Genome Atlas

Acknowledgments
We thank the Western Australia Cancer and Palliative Care Network for supporting some of the whole exome sequencing in this study. This work was supported by the Australian National Health and Medical Research Council (project grants 1031422 and 1087407) and the Sir Charles Gairdner Hospital Research Advisory Committee. TwinsUK received funding support from the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). TwinsUK also receives support from the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King’s College London.

Funding
Funded by the Western Australia Cancer and Palliative Care Network and the Australian National Health and Medical Research Council Project Grant 1031422.

Authors' contributions
AW carried out analysis of probands and exome sequencing data and drafted the manuscript. SW participated in the design and coordination of the study, provided data from the TwinsUK study and helped to draft the manuscript. LW and JG collected and analysed patient samples and data. JH provided data from the Busselton study. JW conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. 2School of Medicine & Pharmacology, The University of Western Australia, Crawley, WA 6009, Australia. 3Department of Twin Research and Genetic Epidemiology, King’s College London, London SE1 7EH, UK. 4Genetic Services of Western Australia, King Edward Memorial Hospital, Subiaco, WA 6008, Australia. 5School of Paediatrics and Child Health, The University of Western Australia, Crawley, WA 6009, Australia. 6Pathwest Laboratory Medicine WA, Nedlands, WA 6009, Australia. 7School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA 6009, Australia.

Received: 18 December 2015 Accepted: 23 June 2016
Published online: 17 August 2016

References
1. Eberhard NL, et al. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321(1):50–6.
2. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–80.
3. Sadowski SM, et al. Prospective screening in familial nonmedullary thyroid cancer. Surgery. 2013;154(6):1194–8.
4. Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer. 2003;103(1):105–9.
5. Bauer AJ. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. Front Horm Res. 2013;41:141–8.
6. Fan YF, et al. Clinicopathologic features of familial nonmedullary thyroid carcinoma. Chin Med J (Engl). 2015;128(8):1037–41.
7. Navas-Carrillo D, et al. Familial nonmedullary thyroid cancer: Screening, clinical, molecular and genetic findings. Biochem Biophys Acta. 2014;1846(2):468–76.
8. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Cancer Control. 2006;13(2):106–10.
9. McDonald TJ, et al. Familial papillary thyroid carcinoma: a retrospective analysis. J Oncol. 2011;2011:948786.
10. He H, et al. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab. 2013;98(5):E973–80.
11. Bonora E, et al. The FOXE1 locus is a major genetic determinant for familial non-medullary thyroid carcinoma. Int J Cancer. 2013;134(9):2088–107.
12. Ngan ES, et al. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinoiod goiter and papillary thyroid carcinoma. J Natl Cancer Inst. 2009;101(3):162–76.
13. Vries MR, et al. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid. 2009;19(12):1343–9.
14. Burgess JR, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab. 1997;82(2):345–8.
15. Gara SK, et al. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med. 2015;373(5):484–8.
16. Zhao X, Li X, Zhang X. HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med. 2015;373(21):2084–7.
17. Zhou E, Lin ZY, Yang Y. HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med. 2015;373(21):2084–7.
18. Tomisc J, He H, de la Chapelle A. HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med. 2015;373(21):2084–7.
19. Sponziello M, Durante C, Filetti S. HABP2 Mutation in Papillary Thyroid Cancer. N Engl J Med. 2015;373(21):2084–7.
20. Tomisc J, et al. HABP2 G534E Variant in Papillary Thyroid Carcinoma. PLoS One. 2016;11(11):e0164315.
21. Sahasrabudhe R, et al. The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. J Clin Endocrinol Metab. 2015. p. jc0153928.
22. Alzahrawi AS, et al. HABP2 gene mutations do not cause familial or sporadic non-medullary thyroid cancer in a highly inbred Middle Eastern population. Thyroid. 2016;26(5):667–71.
23. Zhang T, Xing M. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer. J Natl Cancer Inst. 2016;108(6):djv415.
24. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
25. Teer JK, et al. VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. Bioinformatics. 2012;28(4):599–600.
26. Taylor PN, et al. Whole-genome sequence-based analysis of thyroid function. Nat Commun. 2015;6:5681.
27. De Jong SA, et al. Thyroid carcinoma and hyperparathyroidism after radiation therapy for adolescent acne vulgaris. Surgery. 1991;110(4):691–5.
28. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16(2):181–6.
29. Ahmad-Nejad P, et al. The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events. Thromb Res. 2012;130(3):441–4.
30. Sedding D, et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med. 2006;203(13):2801–7.